Q1 FY27 Results: Net Loss of Rs 57.32 Lacs vs Profit Last Year

Pat NegativeEbitda Margin CompressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹0.55

prior close

₹0.54

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-1.3% vs market

Pharmaceuticals & Biotechnology peers, median of 170sector · industry level-0.0%+0.0% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and in line with its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+1.9

15m

+0.0

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+1.3-1.3-0.0+0.0

Next day

-1.8+1.6-3.5+0.2-2.0

+0.0+1.7-1.7+0.5-0.5

-3.6+1.6-5.3+1.0-4.7

-1.8+1.5-3.3+1.2-3.0

-5.5+1.8-7.3+1.0-6.5

-5.5+2.1-7.5+0.5-5.9

15d

-7.3+3.2-10.5-0.0-7.3

-5.5+3.7-9.2+1.7-7.2

-14.5+1.1-15.7+0.9-15.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals & Biotechnology peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shree Ganesh Biotech reported Q1 FY27 results with revenue up 3% YoY at Rs 142.99 lacs. Total expenses climbed to Rs 232.32 lacs from Rs 147.19 lacs a year ago, pushing the company to a net loss of Rs 57.32 lacs versus a profit of Rs 32.70 lacs in Q1 FY26. EPS stood at minus Rs 0.01. Statutory auditors gave a clean limited review.

Likely market impact

Sharp swing to loss shows rising cost pressure and shrinking margins. Watch upcoming quarters for recovery signs.